Role Of Myo-Inositol Supplementation in prevention of Gestational Diabetes Mellitus in parturient women at risk.

  • Anam Mumtaz PIMS
  • Ainy Senior Registrar MCH Centre, Unit 1,Pakistan Institute of Medical Sciences,Islamabad.
  • Musarrat Batool Assistant Professor,MCH Centre, Unit 1Pakistan Institute of Medical Sciences Islamabad 
  • Shirza Sharafat Ali Senior Registrar MCH Center, Unit I Pakistan Institute of Medical Sciences Islamabad 
  • Shagufta Yasmin Associate Professor, MCH Center, Unit I, Pakistan Institute of Medical Sciences, Islamabad
  • Naila Israr Consultant Gynaecologist, Federal Govt services Hospital, PGMI, Islamabad
Keywords: Gestational diabetes, Myo-Inositol supplementation

Abstract

Objective: To assess the frequency of gestational diabetes mellitus in parturient women at risk after supplementation of Myo-Inositol as compared to placebo.

Methodology: This randomized controlled trial was conducted in the Outpatient Department of Obstetrics and Gynecology, PIMS, Islamabad from July 2020 to January 2021. A total of 120 pregnant women, irrespective of parity in the first trimester, who had 1 or more first-degree relative diagnosed with diabetes mellitus, and were overweight (BMI >25 kg/m2) or obese (BMI >30 kg/m2) at their first antenatal visit were selected. Women with already diagnosed with diabetes mellitus were excluded. Starting from the end of the first trimester or the start of the second trimester (12-15 weeks of gestation) the intervention group was supplemented with 2g Myo-Inositol and 200 mcg Folic acid twice daily as compared to placebo which was given only 200 mcg Folic acid twice daily. Between 24-48 weeks, they were tested for 75gm 2 hour OGTT.

Results: The mean age of women in interventional group was 27.78 ± 4.07 years and in the placebo group was 28.88 ± 4.19 years. The mean gestational age was 9.33 ± 1.90 weeks in intervention group and 9.52 ± 1.85 weeks in the placebo group. In this study, the frequency of gestational diabetes mellitus in parturient women at risk after supplementation of Myo-Inositol was 16.67% as compared to 36.67% in placebo (p-value, 0.01).

Published
2023-01-11
Section
Original Articles